X4 Pharmaceuticals, Inc. XFOR
Set alert
3.35 USD 0.00 0.00%
At close · Nov 2
3.35 0.00 0.00%
After hours · Nov 2, 4:33 PM ET
3.26 Day range 3.47
2.43 52-week range 4.83
- YTD
- -16.25%
- 1 year
- -17.08%
- Open
- 3.40
- Prev close
- 3.35
- Mkt cap
- 332.14M
- Vol
- 521.46K
- Avg vol
- 858.69K
- EPS
- 0.02
- P/E
- 167.50
- Div yield
- 0.00%
More statistics
- Low
- 3.26
- High
- 3.47
- Forward P/E
- -1.23
- Beta
- 0.39
- Short ratio
- 8.64
- Inst. own
- 67.66%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.50158
- 200-d avg
- 0.79766
- 1y target
- 3.05
5Y chart
Events in this range
- Mar 21, 2024Earnings: -0.1; estimate -0.15; surprise 33.33%
- Mar 22, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Apr 30, 2024Rating: HC Wainwright & Co. · Buy → Buy
- May 7, 2024Earnings: -0.26; estimate -0.17; surprise -52.94%
- May 7, 2024Earnings: —; estimate -0.17; surprise —%
- May 31, 2024Rating: Cantor Fitzgerald · Overweight → Overweight
- Jun 28, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 8, 2024Earnings: -0.07; estimate -0.05; surprise -40%
- Aug 8, 2024Earnings: —; estimate -0.05; surprise —%
- Nov 13, 2024Earnings: -0.18; estimate -0.17; surprise -5.88%
- Nov 14, 2024Rating: Stifel · Buy → Buy
- Nov 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Apr 28, 2025Split: 1 for 30
Signals (83)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| MACD: Buy Signal | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 25, 2026 | 5 months ago |
| SMA: Bearish | May 11, 2026 | 5 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bearish | Feb 3, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 27, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bullish | Dec 23, 2024 | 1 year ago |
| SMA: Bearish | Dec 16, 2024 | 1 year ago |
| SMA: Bullish | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Dec 9, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 9, 2024 | 1 year ago |
| SMA: Bearish | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | May 27, 2024 | 2 years ago |
| SMA: Bearish | May 13, 2024 | 2 years ago |
| MACD: Sell Signal | May 13, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| SMA: Bullish | Mar 11, 2024 | 2 years ago |
| SMA: Bearish | Mar 4, 2024 | 2 years ago |
| SMA: Bullish | Feb 26, 2024 | 2 years ago |
| SMA: Bullish | Jan 29, 2024 | 2 years ago |
| SMA: Bearish | Jan 15, 2024 | 2 years ago |
| SMA: Bullish | Jan 8, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 25, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 25, 2023 | 2 years ago |
| SMA: Bearish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| RSI: Oversold | Oct 23, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 24, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 10, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 10, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 5, 2022 | 3 years ago |
| SMA: Bearish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 21, 2022 | 3 years ago |
| SMA: Bullish | Sep 26, 2022 | 4 years ago |
| SMA: Bullish | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 12, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Jul 18, 2022 | 4 years ago |
| SMA: Bearish | Apr 4, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
| SMA: Bearish | Mar 14, 2022 | 4 years ago |
| SMA: Bullish | Feb 28, 2022 | 4 years ago |
Key statistics
- Market cap
- 98.42M
- Enterprise value
- 9.24M
- Trailing P/E
- 0.00
- Forward P/E
- -1.23
- PEG ratio
- 0.00
- Price / sales
- 174.82
- Price / book
- 1.89
- EPS (TTM)
- -0.08
- Beta
- 0.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 3131.79%
- Revenue (TTM)
- 563.00K
- Revenue growth
- 0.00%
- Free cash flow
- -71.71M
- Total cash
- 168.75M
- Total debt
- 78.23M
- Return on equity
- 21.77%
- Shares outstanding
- 170.55M
- Short % of float
- 6.84%
- 50-day average
- 0.50158
- 200-day average
- 0.79766
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 3.05 -9.0% downside
Now 3.35
- Target (low)
- 1.50
- Target (mean)
- 3.05
- Target (high)
- 4.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.1575.
Financials — quick view
XFOR Revenue — quarterly 8.81M
XFOR Net income — quarterly -16.16M
XFOR EPS — quarterly -0.13
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.17 | -0.18 | -0.01 | -5.88% |
| Aug 8, 2024 | Jun 1, 2024 | -0.05 | -0.07 | -0.02 | -40.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.05 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.17 | -0.26 | -0.09 | -52.94% |
| May 7, 2024 | Mar 1, 2024 | -0.17 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.15 | -0.10 | +0.05 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 14, 2024 | Stifel | main | Buy | Buy |
| Jun 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Apr 30, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- x4pharma.com
News
- X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
- X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
- X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
- Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)
- X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
- X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated “Moderate Buy” by Sell-Side Brokerages
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages
Your note
Sign in to keep a note on XFOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALISKI WILLIAM E | Director | Stock Award(Grant) | Jun 9, 2024 | 96,667 |
| BALDRY MARK | Officer | Sale | Oct 6, 2024 | 48,509 |
| DE CRAECKER FRANCOISE | Director | Stock Award(Grant) | Jun 9, 2024 | 96,667 |
| DIBIASE MARY | Chief Operating Officer | Sale | Oct 6, 2024 | 452,060 |
| MCGIRR DAVID W J | Director | Stock Award(Grant) | Jun 9, 2024 | 96,667 |
| MOSTAFA ADAM S. | Chief Financial Officer | Sale | Oct 6, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 9.92% | 16,915,784 | 9.76M | Sep 29, 2024 |
| NEA Management Company, LLC | 8.79% | 14,986,793 | 8.65M | Sep 29, 2024 |
| Blackrock Inc. | 6.57% | 11,210,671 | 6.47M | Sep 29, 2024 |
| Vanguard Group Inc | 4.95% | 8,440,730 | 4.87M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 4.18% | 7,133,515 | 4.12M | Sep 29, 2024 |
| Kingdon Capital Management LLC | 2.72% | 4,638,683 | 2.68M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 5,034,386 | 2.91M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.46% | 4,195,788 | 2.42M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.14% | 1,935,936 | 1.12M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.02% | 1,739,242 | 1.00M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.96% | 1,639,835 | 946.35K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 731,215 | 421.98K | Oct 30, 2024 |